US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Latest News about Treatment Resistant Depression

Recent news which mentions Treatment Resistant Depression

Building Australia's Psychedelics Industry: A New Joint Venture And Why It's Important
Tags News Cannabis Market News
From Benzinga
atai Life Sciences' Drug Trial For Depression Fails To Deliver Expected Results, Stock Plunges
Tickers ATAI
Tags Perception Neuroscience Treatment Resistant Depression Ketamine Therapy
From Benzinga
What Happened With Psychedelics In The Last Year? 11 Key News Items, The Sector's Performance & Takeaways
Tickers ATAI AWKNF CMND CMPS
Tags MYCOF ENVB CYBN
From Benzinga
Phase 2 Trial For This Psychedelic, Potential Treatment For Severe Depression
Tags News Cannabis Market News
From Benzinga
Next-Gen Psychedelic Delivers Promising Results For Treatment-Resistant Depression In Phase 2 Clinical Trial
Tickers BMNDF
Tags Market News Cannabis Markets
From Benzinga
Atai's Phase 2 Study For Treatment-Resistant Depression Completes Enrollment, Expects Results Soon
Tickers ATAI
Tags Benzinga Ketamine ATAI
From Benzinga
GH Research Shares Q2 2022 Financial Results & Business Updates
Tickers GHRS
Tags GH001 Earnings Psychedelics
From Benzinga
Major Goals For ATAI: $175M Secured In Term Loan Facility, Plus Q2 Earnings Report
Tickers ATAI HTGC
Tags Mid Cap HTGC Financing
From Benzinga